Evidence map›Paper›PMID 30618712›Full record

ArticleFrontiers in aging neuroscience2018

Unbiased Proteomic Approach Identifies Unique and Coincidental Plasma Biomarkers in Repetitive mTBI and AD Pathogenesis.

Joseph O Ojo, Gogce Crynen, Jon M Reed, Rosa Ajoy, Prashanthi Vallabhaneni, Moustafa Algamal, Paige Leary, Naomi G Rafi, Benoit Mouzon, Michael Mullan and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in aging neuroscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Clinical Trials in Alzheimer's Disease: A Hurdle in the Path of Remedy.International journal of Alzheimer's disease · 2020
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Joseph O OjoExperimental Neuropathology and Proteomic Laboratory, Roskamp Institute, Sarasota, FL, United States.
Gogce CrynenExperimental Neuropathology and Proteomic Laboratory, Roskamp Institute, Sarasota, FL, United States.
Jon M ReedExperimental Neuropathology and Proteomic Laboratory, Roskamp Institute, Sarasota, FL, United States.
Rosa AjoyExperimental Neuropathology and Proteomic Laboratory, Roskamp Institute, Sarasota, FL, United States.
Prashanthi VallabhaneniExperimental Neuropathology and Proteomic Laboratory, Roskamp Institute, Sarasota, FL, United States.
Moustafa AlgamalExperimental Neuropathology and Proteomic Laboratory, Roskamp Institute, Sarasota, FL, United States.
Paige LearyExperimental Neuropathology and Proteomic Laboratory, Roskamp Institute, Sarasota, FL, United States.
Naomi G RafiExperimental Neuropathology and Proteomic Laboratory, Roskamp Institute, Sarasota, FL, United States.
Benoit MouzonExperimental Neuropathology and Proteomic Laboratory, Roskamp Institute, Sarasota, FL, United States.
Michael MullanExperimental Neuropathology and Proteomic Laboratory, Roskamp Institute, Sarasota, FL, United States.
Fiona CrawfordExperimental Neuropathology and Proteomic Laboratory, Roskamp Institute, Sarasota, FL, United States.
Roskamp Institute · USThe Open University · GBJames A. Haley Veterans' Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The relationship between repetitive mild traumatic brain injury (r-mTBI) and Alzheimer's disease (AD) is well-recognized. However, the precise nature of how r-mTBI leads to or precipitates AD pathogenesis is currently not understood. Plasma biomarkers potentially provide non-invasive tools for detecting neurological changes in the brain, and can reveal overlaps between long-term consequences of r-mTBI and AD. In this study we address this by generating time-dependent molecular profiles of response to r-mTBI and AD pathogenesis in mouse models using unbiased proteomic analyses. To model AD, we used the well-validated hTau and PSAPP(APP/PS1) mouse models that develop age-related tau and amyloid pathological features, respectively, and our well-established model of r-mTBI in C57BL/6 mice. Plasma were collected at different ages (3, 9, and 15 months-old for hTau and PSAPP mice), encompassing pre-, peri- and post-"onset" of the cognitive and neuropathological phenotypes, or at different timepoints after r-mTBI (24 h, 3, 6, 9, and 12 months post-injury). Liquid chromatography/mass spectrometry (LC-MS) approaches coupled with Tandem Mass Tag labeling technology were applied to develop molecular profiles of protein species that were significantly differentially expressed as a consequence of mTBI or AD. Mixed model ANOVA after Benjamini-Hochberg correction, and a stringent cut-off identified 31 proteins significantly changing in r-mTBI groups over time and, when compared with changes over time in sham mice, 13 of these were unique to the injured mice. The canonical pathways predicted to be modulated by these changes were LXR/RXR activation, production of nitric oxide and reactive oxygen species and complement systems. We identified 18 proteins significantly changing in PSAPP mice and 19 proteins in hTau mice compared to their wild-type littermates with aging. Six proteins were found to be significantly regulated in all three models, i.e., r-mTBI, hTau, and PSAPP mice compared to their controls. The top canonical pathways coincidently changing in all three models were LXR/RXR activation, and production of nitric oxide and reactive oxygen species. This work suggests potential biomarkers for TBI and AD pathogenesis and for the overlap between these two, and warrant targeted investigation in human populations. Data are available via ProteomeXchange with identifier PXD010664.

Indexed as

Alzheimer’s diseasehTaumild-TBIplasma biomarkerproteomicsPS1/APP

Identifiers

PMID30618712
PMCPMC6305374
OpenAlexW2904259852

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.